As it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1

With a significant jump in cash, High Point ’s public biopharmaceutical company vTv Therapeutics lessened its net loss in the first quarter of 2023 to $4.5 million.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 6, 2023 Category: Pharmaceuticals Authors: Lillian Johnson Source Type: news